Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance

被引:64
作者
Muraki, Ayako [1 ]
Miyashita, Kazutoshi [1 ]
Mitsuishi, Masanori [1 ]
Tamaki, Masanori [1 ]
Tanaka, Kumiko [1 ]
Itoh, Hiroshi [1 ]
机构
[1] Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo, Japan
关键词
statins; coenzyme Q(10); exercise; mitochondria; oxygen utilization; DENSITY-LIPOPROTEIN CHOLESTEROL; SKELETAL-MUSCLE; STATINS; METABOLISM; MYOPATHY; RATS; SUPPLEMENTATION; METAANALYSIS; EXPRESSION; SYMPTOMS;
D O I
10.1152/japplphysiol.01362.2011
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q(10) reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol 113: 479-486, 2012. First published May 31, 2012; doi: 10.1152/japplphysiol.01362.2011.-Statins are cholesterol-lowering drugs widely used in the prevention of cardiovascular diseases; however, they are associated with various types of myopathies. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and thus decrease biosynthesis of low-density lipoprotein cholesterol and may also reduce ubiquinones, essential coenzymes of a mitochondrial electron transport chain, which contain isoprenoid residues, synthesized through an HMG-CoA reductase-dependent pathway. Therefore, we hypothesized that statin treatment might influence physical performance through muscular mitochondrial dysfunction due to ubiquinone deficiency. The effect of two statins, atorvastatin and pravastatin, on ubiquinone content, mitochondrial function, and physical performance was examined by using statin-treated mice. Changes in energy metabolism in association with statin treatment were studied by using cultured myocytes. We found that atorvastatin-treated mice developed muscular mitochondrial dysfunction due to ubiquinone deficiency and a decrease in exercise endurance without affecting muscle mass and strength. Meanwhile, pravastatin at ten times higher dose of atorvastatin had no such effects. In cultured myocytes, atorvastatin-related decrease in mitochondrial activity led to a decrease in oxygen utilization and an increase in lactate production. Conversely, coenzyme Q(10) treatment in atorvastatin-treated mice reversed atorvastatin-related mitochondrial dysfunction and a decrease in oxygen utilization, and thus improved exercise endurance. Atorvastatin decreased exercise endurance in mice through mitochondrial dysfunction due to ubiquinone deficiency. Ubiquinone supplementation with coenzyme Q(10) could reverse atorvastatin-related mitochondrial dysfunction and decrease in exercise tolerance.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 33 条
  • [1] Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism
    Aragones, Julian
    Schneider, Martin
    Van Geyte, Katie
    Fraisl, Peter
    Dresselaers, Tom
    Mazzone, Massimiliano
    Dirkx, Ruud
    Zacchigna, Serena
    Lemieux, Helene
    Jeoung, Nam Ho
    Lambrechts, Diether
    Bishop, Tammie
    Lafuste, Peggy
    Diez-Juan, Antonio
    Harten, Sarah K.
    Van Noten, Pieter
    De Bock, Katrien
    Willam, Carsten
    Tjwa, Marc
    Grosfeld, Alexandra
    Navet, Rachel
    Moons, Lieve
    Vandendriessche, Thierry
    Deroose, Christophe
    Wijeyekoon, Bhathiya
    Nuyts, Johan
    Jordan, Benedicte
    Silasi-Mansat, Robert
    Lupu, Florea
    Dewerchin, Mieke
    Pugh, Chris
    Salmon, Phil
    Mortelmans, Luc
    Gallez, Bernard
    Gorus, Frans
    Buyse, Johan
    Sluse, Francis
    Harris, Robert A.
    Gnaiger, Erich
    Hespel, Peter
    Van Hecke, Paul
    Schuit, Frans
    Van Veldhoven, Paul
    Ratcliffe, Peter
    Baes, Myriam
    Maxwell, Patrick
    Carmeliet, Peter
    [J]. NATURE GENETICS, 2008, 40 (02) : 170 - 180
  • [2] The transcriptional coactivator PGC-1β drives the formation of oxidative type IIX fibers in skeletal muscle
    Arany, Zoltan
    Lebrasseur, Nathan
    Morris, Carl
    Smith, Eric
    Yang, Wenli
    Ma, Yanhong
    Chin, Sherry
    Spiegelman, Bruce M.
    [J]. CELL METABOLISM, 2007, 5 (01) : 35 - 46
  • [3] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [4] Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics
    Bhagavan, HN
    Chopra, RK
    [J]. FREE RADICAL RESEARCH, 2006, 40 (05) : 445 - 453
  • [5] Bisgaier CL, 1997, J LIPID RES, V38, P2502
  • [6] Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study
    Bruckert, E
    Hayem, G
    Dejager, S
    Yau, C
    Bégaud, B
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) : 403 - 414
  • [7] Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins
    Caso, Giuseppe
    Kelly, Patricia
    McNurlan, Margaret A.
    Lawson, William E.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (10) : 1409 - 1412
  • [8] Suppression of Mitochondrial Function by Oxidatively Truncated Phospholipids Is Reversible, Aided by Bid, and Suppressed by Bcl-XL
    Chen, Rui
    Feldstein, Ariel E.
    McIntyre, Thomas M.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (39) : 26297 - 26308
  • [9] Muscle fatigue from losing your PHD
    Dang, Chi V.
    Gao, Ping
    [J]. CELL METABOLISM, 2008, 7 (03) : 191 - 192
  • [10] Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice
    de Haan, Willeke
    van der Hoogt, Caroline C.
    Westerterp, Marit
    Hoekstra, Menno
    Dallinga-Thie, Geesje M.
    Princen, Hans M. G.
    Romijn, Johannes A.
    Jukema, J. Wouter
    Havekes, Louis M.
    Rensen, Patrick C. N.
    [J]. ATHEROSCLEROSIS, 2008, 197 (01) : 57 - 63